Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

Leukemia. 2010 Aug;24(8):1523-5. doi: 10.1038/leu.2010.122. Epub 2010 Jun 3.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Female
  • Humans
  • Indoles / therapeutic use*
  • Leukemia, Myelomonocytic, Chronic / drug therapy
  • Leukemia, Myelomonocytic, Chronic / genetics*
  • Mutation*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Sorafenib
  • Sunitinib
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • Sunitinib